- March 29, 2012: Bryan  Garnier initiates coverage of Hybrigenics with a target price of € 2.6

- March 29, 2012: BRYAN GARNIER Financial Analysis

- March 27, 2012: Hybrigenics completed its private placement to institutional investors up to EUR 3.3 million

- March 13, 2012: Hybrigenics gets approval and financing for a Phase II clinical trial of oral inecalcitol in chronic lymphocytic leukemia (CLL)

- February 27, 2012: Hybrigenics obtains patent protection for an improved chemical synthesis of inecalcitol

- January 30, 2012: Hybrigenics revenues grew 45% to EUR 6.6 million in 2011

- January 19, 2012: Hybrigenics targets chronic lymphocytic leukemia (CLL) as the third therapeutic indication for its oral inecalcitol

- December 19, 2011: Hybrigenics complete enrolment of its Phase II clinical trial of inecalcitol in psoriasis

- November 21, 2011: Hybrigenics starts Phase II clinical trial of inecalcitol in psoriasis

- October 05, 2011: Hybrigenics appoints Dr. Alain Munoz to its Board of directors

- October 10, 2011: Hybrigenics and Servier enter into a licence and research collaboration agreement in oncology and other therapeutic fields

- October 28, 2011: Hybrigenics' specific inhibitor of Ubiquitin-Specific Protease 7 (USP7) is cytotoxic for Chronic Lymphocytic Leukaemia (CLL) cells in vitro

- September 06, 2011: Hybrigenics gets approval and funding for a Phase II clinical trial of inecalcitol in psoriasis

- April 27, 2011: Hybrigenics’ inecalcitol inhibits the growth of human hormone-dependent prostate cancer cells in vitro and in vivo

- May 31, 2011: Hybrigenics to present inecalcitol results at the ASCO annual meeting